In a follow-up on the progress on French company, Valneva’s Lyme disease vaccine candidate VLA15, the company expects to launch a Phase 2 study in the second half of 2018, subject to regulatory...

In a follow-up on the progress of the Lyme disease vaccine candidate VLA15, French company, Valneva announced today that the U.S. Food and Drug Administration (FDA) has granted the vaccine Fast Track...